The Role of Models Within Economic Analysis
- 58 Downloads
Economic analysis of healthcare interventions is increasingly reliant on decision models to estimate the long- term costs and benefits of new therapies. Models permit analysts to take short-term clinical data to forecast long-term costs and benefits. Models should follow certain basic principles and can be appraised in terms of three broad characteristics: clinical relevance, transparency and analytical ability. The purpose of this paper is to explore the role of modelling in the economic analysis of interventions for type 2 diabetes mellitus. A review of existing models for diabetes identified five complex disease models appropriate for economic analysis. These models were broadly similar in structure and in source of input parameters. However, models did vary according to the coverage of relevant disease complications and the complexity of analysis possible. Models could be enhanced by improving their transparency and by using data relevant to type 2 diabetes. In addition, enhancing clinical knowledge through the provision of long-term data on effectiveness may reduce concern relating to the appropriateness of the assumptions currently required within models. The value of such further information must be weighed against the costs of its acquisition.
KeywordsDiabetic Retinopathy Economic Analysis Pioglitazone Diabetes Complication Troglitazone
Funding was provided by Eli Lilly Canada Inc. The authors had independent control over the contents of the manuscript.
- 8.Aronoff S, Rosenblatt S, Braithewaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23 (11): 1605–11PubMedCrossRefGoogle Scholar
- 9.Pinaire J, Robertson K, Zagar A, et al. Favourable impact of pioglitazone on lipid profile independent of baseline triglyceride in type 2 diabetes mellitus. Presented at the Endocrine Society Meeting; 2001 Jun; Denver (CO)Google Scholar
- 13.Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee, including major submissions involving economic analyses. Canberra: Australian Government Publishing Press, 1995Google Scholar
- 14.CCOHTA Guidelines for economic evaluation of pharmaceuticals: Canada. 2nd ed. Ottawa: CCOHTA, 1997Google Scholar
- 29.Palmer AJ, Sendi PP, Spinas GA. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycemic control with metformin versus conventional control in overweight patients with type 2 diabetes. Schweiz Med Wochenschr 2000; 130 (27–28): 1034–40PubMedGoogle Scholar
- 34.Humphrey LL, Ballard DJ, Frohnert PP, et al. Chronic renal failure in non-insulin dependent diabetes mellitus: a population-based study in Rochester, Minnesota. Ann Intern Med 1989; 11: 788–96Google Scholar